
Viela Bio, Inc. VIE
Country |
|
IPO year |
2019 |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBAL |
Shares |
12.3 M |
Market Cap[1] |
$ 2.91 B |
EBITDA (LTM) |
$ 57.6 M |
P/E (LTM) |
- |
P/S (LTM) |
- |
EPS (LTM) |
- |
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
|
Savara
SVRA
|
$ 4.7 | 4.8 % | $ 1.05 B | Nasdaq Global Select Market | ||
|
Teligent, Inc.
TLGT
|
- | -13.85 % | $ 16.1 M | Nasdaq Global Select Market | ||
|
Sutro Biopharma
STRO
|
$ 8.47 | -5.04 % | $ 72 M | Nasdaq Global Select Market | ||
|
Tarsus Pharmaceuticals
TARS
|
$ 75.97 | -2.85 % | $ 3.17 B | Nasdaq Global Select Market | ||
|
Supernus Pharmaceuticals
SUPN
|
$ 36.28 | 1.88 % | $ 2.05 B | Nasdaq Global Select Market,SPB | ||
|
TG Therapeutics
TGTX
|
$ 66.13 | 5.45 % | $ 9.54 B | Nasdaq Capital Market | ||
|
Aphria Inc.
APHA
|
- | -0.45 % | $ 4.87 B | Nasdaq Global Select Market | ||
|
Aerpio Pharmaceuticals, Inc.
ARPO
|
- | -0.90 % | $ 104 M | Nasdaq Capital Market | ||
|
Chiasma, Inc.
CHMA
|
- | -6.00 % | $ 238 M | Nasdaq Global Select Market | ||
|
Adamas Pharmaceuticals, Inc.
ADMS
|
- | - | $ 376 M | Nasdaq Global Market | ||
|
Cellect Biotechnology Ltd.
APOP
|
- | 0.38 % | $ 12.9 M | Nasdaq Global Select Market | ||
|
AzurRx BioPharma, Inc.
AZRX
|
- | 2.07 % | $ 34.4 M | Nasdaq Capital Market | ||
|
Cerecor Inc.
CERC
|
- | -1.68 % | $ 283 M | Nasdaq Capital Market | ||
|
Constellation Pharmaceuticals, Inc.
CNST
|
- | - | $ 1.63 B | Nasdaq Global Select Market | ||
|
Auris Medical Holding Ltd.
EARS
|
- | -1.77 % | $ 39.2 M | Nasdaq Capital Market | ||
|
Dicerna Pharmaceuticals, Inc.
DRNA
|
- | 0.34 % | $ 2.98 B | Nasdaq Global Select Market,SPB | ||
|
ERYTECH Pharma S.A.
ERYP
|
- | 1.3 % | $ 27.7 M | Nasdaq Global Select Market | ||
|
GW Pharmaceuticals plc
GWPH
|
- | - | $ 6.81 B | Nasdaq Global Select Market | ||
|
Kadmon Holdings, Inc.
KDMN
|
- | - | $ 1.7 B | Nasdaq Global Select Market | ||
|
Liminal BioSciences
LMNL
|
- | - | $ 256 M | Nasdaq Global Market | ||
|
argenx SE
ARGX
|
$ 940.88 | -0.7 % | $ 57.7 B | Nasdaq Global Select Market | ||
|
Tonix Pharmaceuticals Holding Corp.
TNXP
|
$ 2.86 | -4.25 % | $ 24.3 M | Nasdaq Global Select Market | ||
|
Neos Therapeutics, Inc.
NEOS
|
- | -2.54 % | $ 57.2 M | Nasdaq Global Market | ||
|
Xenetic Biosciences
XBIO
|
$ 1.52 | -5.59 % | $ 2.59 M | Nasdaq Capital Market | ||
|
Odonate Therapeutics, Inc.
ODT
|
- | -3.18 % | $ 58.5 M | Nasdaq Global Select Market | ||
|
Orphazyme A/S
ORPH
|
- | -2.25 % | $ 31.3 M | Nasdaq Global Select Market | ||
|
Osmotica Pharmaceuticals plc
OSMT
|
- | -10.74 % | $ 89.9 M | Nasdaq Global Select Market | ||
|
Pandion Therapeutics, Inc.
PAND
|
- | - | $ 1.77 B | Nasdaq Global Select Market | ||
|
Xenon Pharmaceuticals
XENE
|
$ 37.93 | -2.19 % | $ 3.01 B | Nasdaq Global Select Market | ||
|
Xeris Pharmaceuticals
XERS
|
$ 16.95 | 0.92 % | $ 2.72 B | Nasdaq Global Select Market | ||
|
22nd Century Group
XXII
|
$ 0.38 | -14.05 % | $ 69.9 K | NYSE American | ||
|
Translate Bio, Inc.
TBIO
|
- | - | $ 2.81 B | Nasdaq Global Select Market,SPB | ||
|
Trillium Therapeutics Inc.
TRIL
|
- | - | $ 1.94 B | Nasdaq Capital Market | ||
|
Urovant Sciences Ltd.
UROV
|
- | - | $ 532 M | Nasdaq Global Select Market | ||
|
Acceleron Pharma Inc.
XLRN
|
- | - | $ 10.9 B | Nasdaq Global Market,SPB | ||
|
Zealand Pharma A/S
ZEAL
|
- | 0.52 % | $ 821 M | Nasdaq Global Select Market | ||
|
Zogenix, Inc.
ZGNX
|
- | -4.97 % | $ 664 M | Nasdaq Global Market,SPB | ||
|
Yunhong International
ZGYH
|
- | 0.10 % | $ 92.2 M | Nasdaq Capital Market | ||
|
ZIOPHARM Oncology, Inc.
ZIOP
|
- | -7.58 % | $ 264 M | Nasdaq Global Select Market | ||
|
Taysha Gene Therapies
TSHA
|
$ 3.99 | -0.25 % | $ 1.28 B | Nasdaq Global Select Market | ||
|
Zentalis Pharmaceuticals
ZNTL
|
$ 1.38 | -7.38 % | $ 99.2 M | Nasdaq Global Market | ||
|
Zoetis
ZTS
|
$ 85.52 | 2.44 % | $ 37.9 B | NYSE,SPB | ||
|
Vanda Pharmaceuticals
VNDA
|
$ 3.76 | -1.44 % | $ 222 M | Nasdaq Global Select Market,SPB | ||
|
Vericel Corporation
VCEL
|
$ 58.63 | 1.29 % | $ 2.95 B | Nasdaq Global Select Market,SPB | ||
|
Veracyte
VCYT
|
$ 25.54 | 5.41 % | $ 2.01 B | Nasdaq Global Market,SPB | ||
|
VistaGen Therapeutics
VTGN
|
$ 0.2 | 5.69 % | $ 7.61 M | Nasdaq Global Select Market | ||
|
Viking Therapeutics
VKTX
|
$ 26.19 | -2.59 % | $ 2.95 B | Nasdaq Capital Market | ||
|
Voyager Therapeutics
VYGR
|
$ 1.68 | 10.2 % | $ 98.6 M | Nasdaq Global Select Market | ||
|
Zai Lab Limited
ZLAB
|
$ 22.11 | -6.03 % | $ 24.2 B | Nasdaq Global Select Market |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.